Search
Search Results
##search.searchResults.foundPlural##
-
IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS
1155PDF: 600HTML: 6793 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2268PDF: 1318HTML: 17074Bassan Fig.1: 140Bassan Fig.2: 151Bassan Fig.4: 138Fig.3: 179 -
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1541PDF: 1192HTML: 185 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1504PDF: 930HTML: 218 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2079PDF: 1663HTML: 366 -
HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
1992PDF: 756HTML: 3111 -
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment
1701PDF: 830HTML: 142 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4760PDF: 1757HTML: 2701Untitled: 211 -
Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure Memory Cell Population Of Natural Killer Cells in COVID-19 and Cytomegalovirus Exposure
1135PDF: 906HTML: 286 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2054PDF: 1502HTML: 269 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
462PDF: 239HTML: 77 -
TOLL-LIKE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2553PDF: 858HTML: 17463Fig1 Caligaris: 166Fig.2 Caliga: 198 -
REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2304PDF: 978HTML: 7612Untitled: 272Fig2: 182Fig3: 166Fig4: 178 -
Is laboratory monitoring useful in DOACs management?
825PDF: 794HTML: 106 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1600PDF: 1085HTML: 111 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2152PDF: 1991HTML: 168 -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
4294PDF: 1481HTML: 1547Untitled: 224 -
APLASTIC ANEMIA AND VIRAL HEPATITIS
1245PDF: 527HTML: 23032 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2149PDF: 1463HTML: 261 -
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
4051PDF: 3342HTML: 198 -
THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.
4020PDF: 1139HTML: 1931Fig.1: 215Fig. 2: 107Table 1: 200Table2: 217Table 3: 197 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4291PDF: 1754HTML: 1104 -
REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy
1548PDF: 599HTML: 185 -
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma
2246PDF: 1811HTML: 139 -
ROLE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
2004PDF: 791HTML: 1039 -
OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT
1280HTML: 299PDF: 927Suppl. Files: 442 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2437HTML: 266PDF: 862 -
COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.
2218PDF: 930HTML: 297 -
IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE
2203PDF: 957HTML: 1887 -
CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA
1266PDF: 606HTML: 3070 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2783PDF: 1002HTML: 5513







